Licensing opportunity
The Institute of Cancer Research, London has a wide range of technology for licence or partnering through its Enterprise Unit.
These range from therapeutics to targets, diagnostic biomarkers, devices, technology platforms and software applications.
Therapeutics include novel aurora kinase inhibitors, Gene-directed enzyme prodrug therapy and novel inhibitors of the enzyme B-RAF.
Drug targets include the gene ETV1 in Prostate Cancer, HDAC9, a novel histone deacetylase and Glypican-5 a potential therapeutic target in soft tissue sarcoma, breast carcinoma, lung carcinoma, lymphoma, medulloblastoma and glioblastoma, which is amenable to antibody-mediated therapies and also has potential as a biomarker.
Diagnostic Biomarkers include monoclonal antibodies against Cerb-B2, EGFR and KSR and a prognostic test for multiple myeloma.
Devices available for license include a laboratory tool for rapid and accurate slicing of fresh tissue samples, providing for co-alignment with tissue imaging and a variable aperture collimator for radiotherapy delivery.
For more information about all these opportunities and who to contact for further information, see: http://www.icr.ac.uk/enterprise/opportunities_navon/15525.pdf
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.